Are Neutrophil-Lymphocyte, Platelet-Lymphocyte, and Monocyte-Lymphocyte Ratios Prognostic Indicators in Patients With Chronic Obstructive Pulmonary Disease in Intensive Care Units?

Guler Eraslan Doganay 1, Mustafa Ozgur Cirik 1

1. Anesthesiology and Reanimation, Ataturk Chest Diseases and Thoracic Surgery Training and Research Hospital, Ankara, TUR

Corresponding author: Guler Eraslan Doganay, gulerdoganay@hotmail.com.tr

Abstract

Background and objective

Chronic obstructive pulmonary disease (COPD) is a condition in which the expiratory airflow is restricted and is characterized by inflammation. Recently, inflammation-related biomarkers such as neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and monocyte-lymphocyte ratio (MLR) have been used to predict the prognosis in COPD. The aim of this study was to evaluate the role of biomarkers such as NLR, PLR, and MLR in COPD patients in intensive care and to examine the ability of these markers to predict the prognosis [length of stay in hospital (LOSH), duration of mechanical ventilation (MV), length of stay in ICU (LOS ICU), and mortality].

Methods

A total of 562 patients who were treated in the ICU between 2018 and 2019 were retrospectively reviewed. Among them, 369 were patients with COPD. We evaluated clinical data including patient demographics, Charlson Comorbidity Index (CCI), Acute Physiology and Chronic Health Evaluation II (APACHE II) score, Sequential Organ Failure Assessment (SOFA) score, LOS ICU, LOSH, duration of MV, as well as NLR, PLR, and MLR values. Data on patient deaths (30-day mortality) was obtained from the Death Notification System.

Results

Age, LOSH, CCI, and SOFA were found to predict mortality in COPD patients. In cases with mortality, age, inotropic use, MV duration, LOS ICU, APACHE II, CCI, SOFA, lymphocyte count, neutrophil count, platelet count, monocyte count, NLR, PLR, and MLR levels were statistically significantly higher than those in cases without mortality. There was a positive and low statistically significant relationship of NLR, PLR, and MLR with prognostic factors like MV duration, APACHE II scores, and SOFA scores.

Conclusion

The NLR, PLR, and MLR values may be used as prognostic indicators in COPD patients in intensive care. Although there are many studies endorsing the use of biomarkers such as NLR, PLR, and MLR as prognostic indicators, further comparative studies on this subject are still required to gain deeper insights into the topic.

Introduction

Chronic obstructive pulmonary disease (COPD) is a condition where the expiratory airflow is restricted and is characterized by inflammation. Although many systemic biomarkers are used in COPD, recently, neutrophil-lymphocyte ratio (NLR), monocyte-lymphocyte ratio (MLR), and platelet-lymphocyte ratio (PLR), which can be calculated from the routine complete blood count, have come to be widely used to predict the prognosis due to their low cost and easy availability [1,2]. The degree of pulmonary inflammation in COPD is strongly related to smoking [3]. In various studies, NLR was reported to be high in patients with COPD exacerbation. Comorbidities and extrapulmonary symptoms also affect the survival and severity of disease in COPD patients. Many comorbidities are also associated with inflammation [4,5]. Acute exacerbation of COPD (AECOPD) is characterized by more severe inflammation compared to stable patients and may
increase the length of stay in hospital (LOSH) and length of stay in ICU (LS ICU), and may also require more invasive treatments such as mechanical ventilation (MV) [6,7].

Previous studies on NLR and COPD have shown that NLR affects airflow limitation, the severity of the disease, exacerbation, LOSH, and mortality [8-11]. The aim of this study was to evaluate the role of biomarkers such as NLR, PLR, and MLR in COPD patients in intensive care and to investigate the ability of these markers to predict the prognosis (LOSH, duration of MV, LS ICU, and mortality).

Materials And Methods

After obtaining ethical approval from the Medical Specialization Training Board of Ataturk Chest Diseases and Thoracic Surgery Training and Research Hospital (15/10/2020-697), 562 patients treated in the pulmonary ICU during the two-year period between 2018 and 2019 were retrospectively reviewed. Of them, 369 had a history of COPD. We evaluated clinical data including patient demographics, Charlson Comorbidity Index (CCI), Acute Physiology and Chronic Health Evaluation II (APACHE II) scores, Sequential Organ Failure Assessment (SOFA) scores, LOS ICU, LOSH, duration of MV, as well as NLR, PLR, and MLR values. Data on patient deaths (30-day mortality) was obtained from the Death Notification System.

The inclusion criteria were as follows: all COPD patients who needed non-invasive or invasive MV in the ICU. Patients with severe lung diseases such as asthma, bronchiectasis, tuberculosis, and malignancy were excluded from the study.

Statistical methods

The results were compared using SPSS Statistics version 22.0 (IBM, Armonk, NY). Whether the distribution of continuous variables was normal or not was determined by the Kolmogorov-Smirnov test. Continuous data were described as mean ± SD and median (interquartile range) for skewed distributions. Categorical data were presented as numbers and percentages. Categorical variables were compared using Pearson’s chi-squared test or Fisher’s exact test.

Firstly, possible risk factors that were thought to be related to mortality were analyzed via one variable multinomial logistic regression analysis. Variables with p<0.25 in the univariate logistic regression analysis were included in multivariate logistic regression analysis. The Backward Wald method was used for multivariate logistic regression analysis. The receiver operating characteristic (ROC) curve analysis was used to determine the cut-off points. A p-value <0.05 was considered statistically significant and a p-value between 0.05 and 0.10 was deemed to be borderline significant level on all statistical analyses.

Results

In order to determine the factors affecting mortality in COPD patients, logistic regression analysis of single variables was performed first (univariate analysis). Variables with p<0.25 in the univariate logistic regression analysis were included in multivariate logistic regression analysis. The Backward Wald method was used for multivariate logistic regression analysis. The results of step 5, which is the last step of the analysis, are given in Table 1. According to the results, it was determined that age, LOSH, CCI, and SOFA affected mortality in COPD patients.
### TABLE 1: The factors affecting mortality in COPD patients

Multinomial logistic regression nagelkerke $R^2=0.512$ (Hosmer-Lemeshow $p>0.05$)

COPD: chronic obstructive pulmonary disease; OR: odds ratio; LOSH: length of stay in hospital; LOS ICU: length of stay in intensive care unit; MV: mechanical ventilation; APACHE II: Acute Physiology and Chronic Health Evaluation II; CCI: Charlson Comorbidity Index; SOFA: Sequential Organ Failure Assessment

The ROC curve analysis was applied to determine the success of NLR, PLR, and MLR in predicting mortality and to give the cut-off value for mortality in COPD patients. It showed that it could distinguish between NLR cases in determining the risk of mortality; that is, it can correctly classify the patients at a rate of 63%, 61.4%, and 63.4% (intermediate level), respectively. In order to answer the question as to which value should be taken as the cut-off value for this test, the sensitivity and specificity values obtained as a result of the analysis were examined and the optimum point was selected.

The sensitivity value for NLR was 40.3%, the specificity value was 80.9%, and the cut-off value was 21.71. As a result, the risk of mortality was higher in cases with NLR 21.71 and above. The sensitivity value for PLR was 47%, the specificity value was 75.3%, and the cut-off value was 423.54. As a result, the risk of mortality was higher in cases with PLR 423.54 and above. The sensitivity value was 53.7% for MLR, the specificity value was 71.9%, and the cut-off value was 0.873. As a result, the risk of mortality was higher in cases with MLR 0.873 and above (Table 2). Figure 1 also presents the ROC curve analysis.

### TABLE 2: ROC curve analysis for predicting mortality

ROC: receiver operating characteristic; AUC: area under the curve
FIGURE 1: ROC curve analysis

ROC: receiver operating characteristic

As per the comparison between the cases with mortality and those without mortality, age, inotropic use, MV duration, LOS ICU, APACHE II, CCI, SOFA, lymphocyte count, neutrophil count, platelet count, monocyte count, NLR, PLR, and MLR levels were found to be statistically significantly higher in the mortality group (Table 3).
| Variables (n=369) | Mortality (n=126) | No mortality (n=243) | P-value |
|------------------|------------------|---------------------|--------|
| Gender, n (%)    |                  |                     |        |
| Male             | 86 (64.2%)       | 144 (61.3%)         | 0.580  |
| Female           | 48 (35.8%)       | 91 (38.7%)          |        |
| Inotropic use, n (%) | 70 (52.2%)     | 18 (7.7%)           | <0.001 |
| Malignancy, n (%) | 12 (9%)          | 14 (6%)             | 0.279  |
| Age              | 74.22 ±11.23     | 70.87 ±11.26        | 0.003  |
| MV duration      | 5.25 ±7.24       | 3 (2)               | <0.001 |
| LOS ICU          | 7.03 ±6.89       | 4.90 ±6.57          | 0.003  |
| LOSH             | 18.84 ±13.26     | 21.23 ±16.60        | 0.235  |
| APACHE II score  | 25.55 ±8.00      | 19.59 ±6.05         | <0.001 |
| CCI              | 6.67 ±2.09       | 5.72 ±1.79          | <0.001 |
| SOFA score       | 7.34 ±2.68       | 4.88 ±1.56          | <0.001 |
| Lymphocyte count | 0.97 ±1.18       | 1.09 ±0.89          | 0.008  |
| Neutrophil count | 12.62 ±7.69      | 9.76 ±6.31          | <0.001 |
| Platelet count   | 275.40 ±138.18   | 238.68 ±101.71      | 0.041  |
| Monocyte count   | 0.93 ±0.80       | 0.79 ±1.20          | <0.001 |
| Neutrophil-lymphocyte ratio | 25.94 ±30.96 | 16.43 ±30.00 | <0.001 |
| Platelet-lymphocyte ratio | 581.28 ±616.14 | 365.60 ±361.78 | <0.001 |
| Monocyte-lymphocyte ratio | 2.06 ±3.10 | 0.93 ±1.44 | <0.001 |

**TABLE 3: The comparison between cases with mortality and those without mortality**

Continuous variables are expressed as mean ± standard deviation (SD) and median (IQR); categorical variables are expressed as frequency and percentage. Continuous variables were compared using the Mann-Whitney U test and categorical variables were compared using Pearson’s chi-square test or Fisher exact test.

LOSH: length of stay in hospital; LOS ICU: length of stay in intensive care unit; MV: mechanical ventilation; APACHE II: Acute Physiology and Chronic Health Evaluation II; CCI: Charlson Comorbidity Index; SOFA: Sequential Organ Failure Assessment

Spearman correlation analysis was applied to determine the relationship of NLR, PLR, and MLR with other variables of 369 COPD patients in the ICU, and the results are presented in Table 4. Based on Spearman correlation analysis, there was a positive and low statistically significant correlation between NLR and MV duration as well as APACHE II and SOFA scores. There was also a positive and low statistically significant relationship between PLR and MV duration. We also found a positive and low statistically significant relationship between MLR and MV duration as well as APACHE II and SOFA scores.
### TABLE 4: The correlation of NLR, PLR, and MLR with other variables

| Variables        | NLR     | PLR     | MLR     |
|------------------|---------|---------|---------|
| **r**            | 0.041   | -0.011  | 0.030   |
| **p**            | 0.427   | 0.837   | 0.570   |
| **n**            | 369     | 369     | 369     |
| **p**            | 0.032   | 0.016   | 0.059   |
| **n**            | 369     | 369     | 369     |
| LOSH **r**       | 0.054   | 0.760   | 0.256   |
| **p**            | 0.544   | 0.760   | 0.256   |
| **n**            | 369     | 369     | 369     |
| **r**            | 0.078   | 0.060   | 0.087   |
| **p**            | 0.137   | 0.247   | 0.097   |
| **n**            | 369     | 369     | 369     |
| **r**            | 0.144   | 0.117   | 0.104   |
| **p**            | 0.006   | 0.024   | 0.046   |
| **n**            | 369     | 369     | 369     |
| **r**            | 0.116   | 0.023   | 0.108   |
| **p**            | 0.026   | 0.660   | 0.039   |
| **n**            | 368     | 368     | 368     |
| **r**            | 0.116   | 0.023   | 0.108   |
| **p**            | 0.026   | 0.660   | 0.039   |
| **n**            | 368     | 368     | 368     |
| **r**            | 0.025   | -0.002  | 0.031   |
| **p**            | 0.628   | 0.964   | 0.553   |
| **n**            | 369     | 369     | 369     |
| **r**            | 0.125   | 0.038   | 0.108   |
| **p**            | 0.016   | 0.465   | 0.037   |
| **n**            | 369     | 369     | 369     |

**NLR**: neutrophil-lymphocyte ratio; **PLR**: platelet-lymphocyte ratio; **MLR**: monocyte-lymphocyte ratio; **LOSH**: length of stay in hospital; **LOS ICU**: length of stay in intensive care unit; **MV**: mechanical ventilation; **APACHE II**: Acute Physiology and Chronic Health Evaluation II; **CCI**: Charlson Comorbidity Index; **SOFA**: Sequential Organ Failure Assessment

### Discussion

This study was conducted to evaluate the utility of NLR, PLR, and MLR as prognostic indicators in patients with COPD. Our findings showed that age, LOSH, CCI, and SOFA affected mortality in COPD patients in ICU. Additionally, in cases with mortality, lymphocyte count, neutrophil count, platelet count, monocyte count, NLR, PLR, MLR were statistically significantly higher than in cases without mortality. Our study also revealed that there was a positive correlation of both NLR and MLR with MV duration, APACHE II scores, and SOFA scores. There was also a positive correlation between PLR and MV duration.

The utility of NLR, PLR, and MLR as prognostic markers has been a topic of controversy in various studies. In 2014, Günay et al. [12] suggested that NLR could be accepted as a new inflammatory marker for COPD patients, and many studies have shown that NLR is associated with airflow limitation, exacerbation, hospitalization, and mortality [13,14]. Lee et al. [10] suggested that NLR may potentially serve as a biomarker in COPD exacerbation because NLR was significantly higher in patients with COPD exacerbation who required hospitalization. This is in line with our findings as we found a correlation of NLR with MV duration, APACHE II scores, and SOFA scores. Lou et al. suggested that elevated NLR and PLR predicted an increased risk of 28-day mortality in patients with AECOPD. However, MLR failed to show any prognostic significance [15]. Controversially, Aksel found that both NLR and PLR are not suitable as prognostic markers in terms of poor clinical outcomes and mortality in COPD exacerbation [16]. Sakurai et al. [14] showed the appropriate cut-off value of NLR to be 2.7 to predict COPD severity and future exacerbations. In our study, we found the cut-off value for predicting mortality to be 2.71.
In patients with COPD, inflammation in the lungs may increase the activation of neutrophils [17]. The NLR value is obtained by dividing the absolute neutrophil count by the absolute lymphocyte count and the test is fairly inexpensive and can be used for screening patients [18]. Some studies have reported that a high PLR is associated with poor prognosis in many physiological stress conditions, especially neonatal sepsis and malignancy [19,20]. In our study, we found a positive and low statistically significant relationship between PLR and MV duration.

Additionally, MLR has recently been used as an indicator of inflammation, morbidity, and mortality [21,22]. Consistent with previous studies on diseases in which inflammation plays an important role in the pathophysiology, such as cardiovascular disease and psoriasis, increased MLR was found to be associated with disease severity [23]. In our study, we found a positive and low statistically significant relationship of MLR with MV duration, APACHE II scores, and SOFA scores.

Limitations of our study include its retrospective nature and single-center design. The present results were derived from short-term follow-ups. We recommend further studies focusing on long-term outcomes to better analyze the topic.

**Conclusions**

Based on our findings, NLR, PLR, and MLR may be used as prognostic indicators in patients with COPD in intensive care. Although many studies have already endorsed the use of biomarkers such as NLR, PLR, and MLR as prognostic indicators, further comparative studies on this subject are required to arrive at more definitive findings.

**Additional Information**

**Disclosures**

**Human subjects:** Consent was obtained or waived by all participants in this study. Medical Specialization Training Board of Ataturk Chest Diseases and Thoracic Surgery Training and Research Hospital issued approval 15/10/2020-697. **Animal subjects:** All authors have confirmed that this study did not involve animal subjects or tissue. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**References**

1. Bozinovski S, Hutchinson A, Thompson M, et al.: Serum amyloid a is a biomarker of acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008, 177:269-78. 10.1164/rccm.200705-678OC
2. Yonchuk JG, Silverman EK, Bowler RP, et al.: Circulating soluble receptor for advanced glycation end products (sRAGE) as a biomarker of emphysema and the RAGE axis in the lung. Am J Respir Crit Care Med. 2015, 192:785-92. 10.1164/rccm.201501-0157PP
3. Ito K, Ito M, Elliott WM, et al.: Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med. 2005; 352:1967-76. 10.1056/NEJMoa041892
4. Vanfleteren LE, Spruit MA, Wouters EF, Franssen FM: Management of chronic obstructive pulmonary disease beyond the lungs. Lancet Respir Med. 2016, 4:911-24. 10.1016/s2213-2600(16)00097-7
5. Miller J, Edwards LD, Agustí A, et al.: Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med. 2013, 107:1576-84. 10.1016/j.rmed.2013.05.001
6. Zhou X, Li Q, Zhou X: Exacerbation of chronic obstructive pulmonary disease. Cell Biochem Biophys. 2015, 73:549-55. 10.1007/s12015-015-0605-9
7. Groenewegen KH, Postma DS, Hop WC, Wilders PL, Schlüsser NJ, Wouters EF: Increased systemic inflammation is a risk factor for COPD exacerbations. Chest. 2008, 133:350-7. 10.1378/chest.07-1542
8. Kim YJ, Lim B, Kyung SY, Park JW, Jeong SH: Comorbidity and inflammatory markers may contribute to predict mortality of high-risk patients with chronic obstructive pulmonary disease exacerbation. J Clin Med Res. 2016, 8:531-6. 10.14740/jcmr2594w
9. Sørensen AK, Holmgard DB, Mygind LJH, Johansen J, Pedersen C: Neutrophil-to-lymphocyte ratio, calprotectin and YKL-40 in patients with chronic obstructive pulmonary disease: correlations and 5-year mortality - a cohort study. J Inflamm (Lond). 2015, 12:20. 10.1186/s12950-015-0064-5
10. Lee H, Um SJ, Kim YS, et al.: Association of the neutrophil-to-lymphocyte ratio with lung function and exacerbations in patients with chronic obstructive pulmonary disease. PLoS One. 2016, 11:e0156511. 10.1371/journal.pone.0156511
11. Furutate R, Ishii T, Motegei T, Hattori K, Kusunoki Y, Gemma A, Kida K: The neutrophil to lymphocyte ratio is related to disease severity and exacerbation in patients with chronic obstructive pulmonary disease. Intern Med. 2016, 55:225-9. 10.2169/internalmedicine.55.5772
12. Güney E, Sarınç Ulaşlı S, Akar O, Ahsen A, Güney S, Koyuncu T, Unlü M: Neutrophil-to-lymphocyte ratio in chronic obstructive pulmonary disease: a retrospective study. Inflammation. 2014, 37:574-80. 10.1007/s10753-013-9749-1
13. Lee SJ, Lee HR, Lee TW, et al.: Usefulness of neutrophil to lymphocyte ratio in patients with chronic obstructive pulmonary disease: a prospective observational study. Korean J Intern Med. 2016, 31:891-8. 10.3904/kjim.2015.084
14. Sakurai K, Chubachi S, Irie H, et al.: Clinical utility of blood neutrophil-lymphocyte ratio in Japanese COPD patients. BMC Pulm Med. 2018, 18:65. 10.1186/s12890-018-0639-z
15. Luo Z, Zhang W, Chen L, Xu N: Prognostic value of neutrophil:lymphocyte and platelet:lymphocyte ratios for 28-day mortality of patients with AECOPD. Int J Gen Med. 2021, 14:2839-48. 10.2147/IJGM.S312045
16. Aksel G: Prognostic value of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in patients who admitted to the emergency department with chronic obstructive pulmonary disease exacerbation. KÜ Tip Fak Derg. 2018, 20:118-24. 10.24938/kutfd.365409
17. Kido T, Tamagawa E, Bai N, et al.: Particulate matter induces translocation of IL-6 from the lung to the systemic circulation. Am J Respir Cell Mol Biol. 2011, 44:197-204. 10.1165/rcmb.2009-0427OC
18. Bhat T, Teli S, Rijal J, et al.: Neutrophil to lymphocyte ratio and cardiovascular diseases: a review. Expert Rev Cardiovasc Ther. 2013, 11:55-9. 10.1586/erc.12.159
19. Can E, Hamilcikan Ş, Can C: The value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio for detecting early-onset neonatal sepsis. J Pediatr Hematol Oncol. 2018, 40:e229-32. 10.1097/MPH.0000000000001059
20. Wu S, Wan Q, Xu R, Zhu X, He H, Zhao X: Systematic review and meta-analysis of the prognostic value of preoperative platelet-to-lymphocyte ratio in patients with urothelial carcinoma. Oncotarget. 2017, 8:91694-702. 10.18632/oncotarget.21162
21. Han LH, Jia YH, Song QX, Wang JB, Wang NN, Cheng YF: Prognostic significance of preoperative lymphocyte-monocyte ratio in patients with resectable esophageal squamous cell carcinoma. Asian Pac J Cancer Prev. 2015, 16:2245-50. 10.7314/apjcp.2015.16.6.2245
22. Murat SN, Yazilogluu M, Celik IE, Kurtul A, Duran M, Kilic A, Oktuz F: The relationship between lymphocyte-to-monocyte ratio and bare-metal stent in-stent restenosis in patients with stable coronary artery disease. Clin Appl Thromb Hemost. 2017, 23:235-40. 10.1177/1076029615627340
23. Cosansu NC, Dikicier BS, Yalbiz M, et al.: Effectiveness of monocyte/lymphocyte ratio in psoriasis. Sakarya Med J. 2020, 10:450-6. 10.31852/smj.719980